AKT1 and cancer: IGFBPs are often deregulated in cancer; IGFBP-2, for example, is often upregulated which intrinsically downregulates phosphatase and tensin homolog (PTEN) (49, 50) removing the inhibitory brake on the PI3K/Akt pathway.